Clinical Trial

A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-07.
Status change: Not Yet Recruiting → Recruiting 2026-03-16
Trial Details
NCT Number NCT07275788
Lead Sponsor Regend Therapeutics
Collaborators: Shanghai Tongji Hospital, Tongji University School of Medicine
Conditions Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Enrollment 15 participants
Start Date 2026-01-08
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-17